Farfield Group Press Releases

01 Apr 2005 - Farfield Pioneers New Approaches to Drug Discovery

Structurally Informed Small Molecule Discovery

Small molecule drugs are targeted at enzyme or receptor binding sites to inhibit function in proteins linked to diseases. To fully understand protein interactions with drug candidate molecules, it is essential to move beyond the simple measurement of affinity parameters towards an understanding of the impact of drug binding on the 3-dimensional structure of the target protein.

Researchers around the world are now using Farfield Sensors’ AnaLight® instrument range to quantitatively measure, in real time, the structural changes in target proteins that result from drug candidate binding. In turn, this enables AnaLight® users to rapidly and continually feed their development pipeline with relevant novel small molecule therapeutics.

Farfield is pleased to be able to release its first set of application notes illustrating the use of the AnaLight® for Structurally Informed Drug Discovery. These notes cover disease-related protease and kinase targets, as well as a model system to explain the theory behind these unique measurements. Farfield’s Marketing Manager, Dr Simon Carrington, adds “ Applications work in this area is naturally highly sensitive and we are very grateful for the permission received from our user base to release this first set of application notes. Combining these advances with those Farfield has recently made in developing lipid membrane mimics for similar studies on membrane-associated proteins once again shows that Farfield is pushing back the frontiers of market-leading analytical measurement for the life scientist.

The application notes related to this release are available to download:

Protease: